Gender-related differences in patients undergoing transcatheter mitral valve interventions in clinical practice: 1-year results from the German TRAMI registry.
Nicolas WernerMiriam PulsStephan BaldusEdith LubosRaffi BekeredjianHorst SievertJoachim SchoferKarl-Heinz KuckHelge MöllmannChristoph HehrleinGeorg NickenigPeter BoekstegersTaoufik OuarrakJochen SengesRalf Zahnnull nullPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
In this analysis from a large prospective, multicenter real-world registry MitraClip® implantation is safe and effective for treatment of significant mitral regurgitation with equal postprocedural results and mortality rates during 1-year follow-up. Men and women showed a persisting and significant clinical benefit at 1-year FU after treatment. Complication and re-intervention rates were low. Additional studies are needed to further evaluate our findings on increased bleeding complications and decreased functional improvement in women at 1-year follow-up after MitraClip® therapy.
Keyphrases
- mitral valve
- patients undergoing
- clinical practice
- left atrial
- left ventricular
- randomized controlled trial
- risk factors
- physical activity
- polycystic ovary syndrome
- atrial fibrillation
- cardiovascular events
- mental health
- cross sectional
- stem cells
- pregnant women
- combination therapy
- pregnancy outcomes
- clinical trial
- double blind
- cervical cancer screening